Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scancell HoldingsSCNLF 19 Cash-to-Debt is 0.53 as of Oct. 2025, which is 91% below its 10-year median of 5.88. GuruFocus rates SCNLF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Scancell Holdings ranks worse than 84.21% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Scancell Holdings's cash to debt ratio for the quarter that ended in Oct. 2025 was 0.53.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Scancell Holdingscouldn't pay off its debt using the cash in hand for the quarter that ended in Oct. 2025.
The historical rank and industry rank for Scancell Holdings's Cash-to-Debt or its related term are showing as below:
SCNLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53 Med: 5.88 Max: No Debt
Current: 0.53
During the past 13 years, Scancell Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.53. And the median was 5.88.
SCNLF's Cash-to-Debt is ranked worse than 84.21% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs SCNLF: 0.53
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Scancell Holdings Cash-to-Debt Related Terms
Scancell Holdings Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SCNLF vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Scancell Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Cash-to-Debt of 0.53 as of Oct. 2025. This is 91% below median its historical median of 5.88. Over the past decade, Scancell Holdings' Cash-to-Debt has ranged from 0.53 to 10,000.00. According to the industry distribution chart, Scancell Holdings ranks #1173 out of 1393 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Scancell Holdings' Cash-to-Debt too high?
Scancell Holdings' current Cash-to-Debt of 0.53 is 91% below median its 10-year median of 5.88. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Scancell Holdings' value of 0.53 is 92.5% below this industry median. Based on the distribution chart, Scancell Holdings ranks #1173 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #1173 out of 1393 companies for Cash-to-Debt. This places Scancell Holdings in the lower half of its industry. The industry median Cash-to-Debt is 7.03. Scancell Holdings' value of 0.53 is 92.5% below this benchmark. Historically, Scancell Holdings' own Cash-to-Debt has ranged from 0.53 to 10,000.00 over the past decade. While the company's 10-year median is 5.88 vs. the industry median of 7.03, Scancell Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scancell Holdings's current Cash-to-Debt of 0.53 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Cash-to-Debt is 0.53, which is 91% below median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Cash-to-Debt of 0.53. The current Cash-to-Debt is 0.53, which is 91% below median its 10-year median of 5.88 and 92.5% below the Biotechnology industry median of 7.03. Scancell Holdings' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Cash-to-Debt is 0.53 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
19GF Score
Get the complete analysis for SCNLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
